Key Segmentation:
By Drug Class
-
NSAIDs
-
Corticosteroids
-
Hyaluronic Acid
-
Disease-Modifying Osteoarthritis Drugs (DMOADs)
-
Opioids
-
Others
By Route of Administration
-
Oral
-
Topical
-
Intra-Articular Injections
-
Others
By End User
-
Hospitals
-
Orthopaedic Clinics
-
Rehabilitation Centres
-
Retail Pharmacies
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
The Osteoarthritis Therapeutics Market is expected to grow at a CAGR of 8.52% from 2026 to 2035.
The Osteoarthritis Therapeutics Market was valued at USD 10.19 Billion in 2025.
The ageing population and obesity epidemic expanding the OA patient pool, advancing DMOAD clinical pipeline targeting disease modification beyond symptom management, and growing intra-articular injection therapy adoption for regenerative medicine applications are the primary growth factors.
NSAIDs dominated the Osteoarthritis Therapeutics Market with the largest share in 2025.
North America dominated the osteoarthritis therapeutics market.